SPONSOR
Bayer
Total Trials
8
Recruiting
8
Phases
Phase 1, Phase 2, Phase 3
Conditions studied: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenHigh-risk Localized Prostate CancerSepsisCoagulopathyAdvanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) ExpressionRetinopathy of PrematurityPreterm InfantsAdvanced Non-small Cell Lung Cancer, HER2 MutationAdvanced Solid Tumors
Bayer is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women, High-risk Localized Prostate Cancer, Sepsis, Coagulopathy.
The trial portfolio spans Phase 1, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Bayer
How many clinical trials has Bayer sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by Bayer, of which 8 are actively recruiting participants. These trials cover conditions including Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women, High-risk Localized Prostate Cancer, Sepsis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Bayer research focus on?
Bayer clinical trials span Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women, High-risk Localized Prostate Cancer, Sepsis, Coagulopathy, Advanced Metastatic Castration-resistant Prostate Cancer, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Bayer clinical trial?
To participate in a Bayer trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Bayer trials with current recruitment status updated daily.
Clinical Trials by Bayer
NCT07762287 Phase 1
Recruiting
Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women
NCT07450599 Phase 2
Recruiting
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
High-risk Localized Prostate Cancer
NCT06854640 Phase 1
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
Sepsis
NCT06217822 Phase 1
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Advanced Metastatic Castration-resistant Prostate Cancer
NCT06315556
Recruiting
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Retinopathy of Prematurity
NCT06452277 Phase 3
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
NCT06760819 Phase 2
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid Tumors
NCT06661122
Recruiting
A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology